# US 2010/0305027 A1 · Cyclic peptides comprising at least one aza-b3-aminoacyl residue and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0305027 A1
- Document ID: US20100305027A1
- Status: Published application
- Kind: A1
- Application number: 12/682,129
- Filed: 2008-10-08
- Published: 2010-12-02
- Earliest claimed: 2007-10-10
- Assignees: Centre National De La Recherche Scientifique; Universite De Rennes I
- Inventors: Mathieu Laurencin; Celine Zatylny-Gaudin; Joel Henry; Michele Baudy Floc'H
- Web page: https://patentgrep.com/patent/US20100305027A1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Cyclic peptides having a random alternation of L-α-aminoacyl residues and aza-β3-aminoacyl residues and their uses.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

Cyclic peptides having a random alternation of L-α-aminoacyl residues and aza-β3-aminoacyl residues corresponding to formula (A) below:
in which
R1 represents a side chain chosen from the group comprising proteogenic and non-proteogenic chains
providing that two L-α-aminoacyl residues are separated by at least one aza-β3-aminoacyl residue and that the total number of the L-α-aminoacyl residues and the aza-β3-aminoacyl residues is comprised between 4 and 8.

### Claim 17 (depends on 16)

Cyclic peptides according to claim 16, characterized in that they are chosen from the hexapeptides and the octapeptides.

### Claim 18 (depends on 16)

Cyclic peptides according to claim 16 characterized in that the L-α-aminoacyl residues are chosen from the group comprising the residues of the following amino acids: arginine, leucine, lysine, phenylalanine, serine, threonine and tryptophan.

### Claim 19 (depends on 16)

Cyclic peptides according to claim 16 characterized in that in the aza-β3-aminoacyl residues of formula (A), R1 represents a side chain chosen from the group comprising natural amino acid residues or non-natural amino acid residues.

### Claim 20 (depends on 19)

Cyclic peptides according to claim 19 characterized in that the natural amino acid residues are chosen from the group comprising arginine, leucine, lysine, phenylalanine, serine, threonine and tryptophan residues.

### Claim 21 (depends on 19)

Cyclic peptides according to claim 19 characterized in that the non-natural amino acid residues are chosen from the group comprising the 1-naphthylalanine [(1)Nal], 2-naphthylalanine [(2)Nal], 4-phenyl-phenylalanine (4Bip), diphenylalanine (Dip), 9-anthracenylalanine [(9)Ath], 4-pyridylalanine [(4)Pal], 3-pyridylalanine [(3)Pal], 2-pyridylalanine [(2)Pal], fluorophenylalanine (4-Fpa), dodecylalanine (Amy), nonylalanine (Non), octylalanine (Oct), cyclohexylalanine (Cha), 4-fluoro-1-naphthylalanine (4-F-1-Nal), homoserine (Hse), and homo-hydroxythreonine, and norleucine (Nle) residues.

### Claim 22 (depends on 16)

Cyclic peptides according to claim 16 having the sequence (Ia):
c[aza-β3aa1′-aa1-aza-β3aa2′-aa2-aza-β3aa3′-aa3-(aza-β3aa4′)m4-(aa4)n4] (Ia)
in which,
each of aa1, aa2, aa3, and aa4 represents independently of each other an L-α-aminoacyl residue,
each of aza-β3aa1′, aza-β3aa2′, aza-β3aa3′ and aza-β3aa4′ represents independently of each other an aza-β3-amino acid, corresponding to formula (A), and
m4 and n4 each simultaneously represent 0 or 1.

### Claim 23 (depends on 16)

Cyclic peptides according to claim 16 having the sequence (Ib):
c[aa1-aza-β3aa1′-aa2-aza-β3aa2′-aa3-aza-β3aa3′-(aa4)n4-(aza-β3aa4′)m4] (Ib)
in which
each of the aa1, aa2, aa3, and aa4 represents independently of each other an L-α-aminoacyl residue,
each of aza-β3aa1′, aza-β3aa2′, aza-β3aa3′ and aza-β3aa4′ represents independently of each other an aza-β3-amino acid, corresponding to formula (A), and
m4 and n4 each simultaneously represent 0 or 1.

### Claim 24 (depends on 16)

Cyclic peptides according to claim 16 having the sequence (Ic):
c(azaβ3aa1′-azaβ3aa2′-azaβ3aa3′-aa1azaβ3aa4′-aa2) (Ic)
in which
each of aa1 and aaz represents independently of each other an L-α-aminoacyl residue,
each of aza-β3aa1′, aza-β3aa2′, aza-β3aa3′ and aza-β3aa4′ represents independently of each other an aza-β3-amino acid, corresponding to formula (A).

### Claim 25 (depends on 16)

Cyclic peptides according to claim 16 having the sequence (Id):
c(azaβ3aa1′-azaβ3aa2′-aa1-azaβ3aa1′-aa2) (Id)
in which
each of aa1 and aaz represents independently of each other an L-α-aminoacyl residue,
each of aza-β3aa1′ and aza-β3aa2′ represents independently of each other an aza-β3-amino acid, corresponding to formula (A).

### Claim 26 (depends on 22)

Cyclic peptides according to claim 22 characterized in that they are chosen from the group comprising the following sequences:
SEQ ID NO 1: c[-Leu-azaβ3Lys-Lys-azaβ3(1)Nal-Leu-
azaβ3(1)Nal-] (NafNaf),
SEQ ID NO 2: c[-Lys-azaβ3Lys-Leu-azaβ3(1)Nal-Leu-
azaβ3(1)Nal-] (NalNal),
SEQ ID NO 3: c[-Lys-azaβ3Lys-Trp-azaβ3Leu-Trp-
azaβ3Leu-] (TrypTryp),
SEQ ID NO 4: c[-Lys-azaβ3Lys-Lys-azaβ3Leu-Trp-
azaβ3Leu-] (3KW),
SEQ ID NO 5: c[-Trp-azaβ3Lys-Lys-azaβ3Lys-Trp-
azaβ3Leu-] (3K2),
SEQ ID NO 6: c[-Lys-azaβ3Lys-Lys-azaβ3Lys-Trp-
azaβ3(1)Nal-] (4KW),
SEQ ID NO 7: c[-Ser-azaβ3(1)Nal-Phe-azaβ3Lys-Thr-
azaβ3Lys-Ser-azaβ3Lys-] (SNalF),
SEQ ID NO 8: c[Leu-azaβ3Arg-Arg-azaβ3(1)Nal-Leu-
azaβ3(1)Nal-] (RNaf),
SEQ ID NO 9: c[-Leu-azaβ3Lys-Lys-azaβ3(1)Nal-]
azaβ3Leu-azaβ3(1)Nal-] (Nafaza)
SEQ ID NO 10: c[-Phe-azaβ3Lys-Lys-azaβ3(1)Nal-
Phe-azaβ3(1)Nal-] (PheNal),
SEQ ID NO 11: c[-Leu-azaβ3Lys-Lys-azaβ3Leu-azaβ3
(1)Nal-] (5pNala),
SEQ ID NO 12: c[-azaβ3Lys-Lys-azaβ3(1)Nal-Leu-
azaβ3(1)Nal-] (5pNafa).
SEQ ID NO 13: c[-Leu-azaβ3Lys-Lys-azaβ3(1)-Nal-
Leu-azaβ3(4F-1)Nal-]( 4Fluo1Naf),
SEQ ID NO 14: c[-Lys-azaβ3Lys-Trp-azaβ3Oct-Trp-
azaβ3Oct-] (OctOct),
SEQ ID NO 15: c[-Lys-azaβ3Lys-Cha-azaβ3Amy-Trp-
azaβ3(1)Nal-] (Chado),
SEQ ID NO 16: c[-Arg-azaβ3Lys-Cha-azaβ3(4)Fpa-Trp-
azaβ3Cha-] (FluoKil),
SEQ ID NO 17: c[-Leu-azaβ3Lys-Lys-azaβ3(2)Nal-Leu-
azaβ3(2)Nal-] (Naf2Naf2),
SEQ ID NO 18: c[-Phe-azaβ3Lys-Arg-azaβ3(2)Nal-Phe-
azaβ3(2)Nal-] (PheNar2),
SEQ ID NO 19: c[-Leu-azaβ3Lys-Lys-azaβ3(1)Nal-Leu-
azaβ3(4)Fluo-(1)Nal-] (4FluoNaf),
SEQ ID NO 20: c[-Leu-azaβ3Lys-Lys-azaβ3Bip-Leu-
azaβ3Bip-] (BipBip),
SEQ ID NO 21: c[-azaβ3Lys-Lys-azaβ3Bip-Leu-
azaβ3Bip-] (5pBip),
SEQ ID NO 22: c[-Leu-azaβ3Arg-Arg-azaβ3(1)Nal-
Leu-] (5pRNaf),
SEQ ID NO 23: c[-Leu-azaβ3Lys-Lys-Leu-azaβ3(1)
Nal-] (5pNafaza),
SEQ ID NO 24: c[-azaβ3Lys-Arg-azaβ3(2)Nal-Phe-
azaβ3(2)Nal-] (5pPheNar2),
SEQ ID NO 25: c[-azaβ3Lys-Lys-azaβ3(2)Nal-Leu-
azaβ3(2)Nal-] (5pNaf2),

### Claim 27 (depends on 16)

Cyclic peptides according to claim 16 as medicaments.

### Claim 28 (depends on 27)

Cyclic peptides according to claim 27 characterized in that the medicament is an anti-infective agent or a disinfectant.

### Claim 29 (depends on 16)

Pharmaceutical composition comprising at least one cyclic peptide according to claim 16 combined with any pharmaceutically acceptable excipient.

### Claim 30 (depends on 16)

Method for the treatment of infections in humans or animals in which microbial cells are brought into contact with at least one cyclic peptide according to claim 16, in a quantity sufficient to cause the death of the microbial cells without causing the death of the cells of said human or said animal.
